Keros Q4 2024 Earnings Report
Key Takeaways
Keros Therapeutics reported revenue of $3.0 million and a net loss of $46.0 million for the fourth quarter of 2024. The increase in net loss was largely due to increased research and development efforts as well as additional investments to support the achievement of Keros' clinical and corporate goals. The company's cash and cash equivalents as of December 31, 2024 was $559.9 million.
Keros received a $200.0 million upfront payment from Takeda for elritercept development.
Initial data from the Phase 1 clinical trial of KER-065 in healthy volunteers is expected in Q1 2025.
Data from the Phase 2 TROPOS trial evaluating cibotercept in patients with pulmonary arterial hypertension is expected.
Cash and cash equivalents as of December 31, 2024, were $559.9 million.
Keros
Keros
Forward Guidance
Based on current operating assumptions, Keros expects that its cash and cash equivalents as of December 31, 2024, together with the $200 million upfront payment from the Takeda Agreement, which the Company received in February 2025, will enable the Company to fund its planned operating expenses and capital expenditure requirements into 2029.